James O’Mara is president and chief executive officer at, Neurogastrx, Inc.
The search continues for a new leader for the FDA’s Center for Drug Evaluation and Research after George Tidmarsh resigned on ...
The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...
The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, ...
The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...
In this episode presented by PII, BioSpace’s head of insights discusses how to relieve clinical trial patients of ...
The court’s decision allows Metsera to walk away from its previous acquisition agreement with Pfizer in favor of Novo Nordisk ...
The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.
Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera: The antitrust ...
In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...
The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall ...
The upheaval of the Health and Human Services workforce and leadership leaves much to be desired in terms of delivery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback